

DR. ADELAÏDE DOUSSAU DE BAZIGNAN, MD, PHD
Postdoctoral research fellow in Bioethics

U.S. Department of Health and Human Services
**Department of Bioethics, Clinical Center,
National Institutes of Health (NIH)**
Building 10, 1C118, Bethesda, MD 20892, USA
Telephone +1 301 594 5523 Email: Adelaide.doussaudebazignan@nih.gov

Research interests: Ethics, design, conduct and analysis of clinical trials and epidemiologic studies; placebo; pragmatic trials.

EDUCATION

PhD in Public Health

2011- 2014

Paris South, Paris Descartes Doctoral School of Public Health

Paris, France

- Thesis: “Oncology dose-finding clinical trials: from optimized designs for continuous inclusion to optimized analysis using ordinal repeated toxicity measurements”
 - Supervisors: Dr X. Paoletti, PhD; Pr R. Thiébaut MD, PhD.
 - Research Laboratory: Institut National de la Santé et de la Recherche Médicale (INSERM) ; INSERM U900 «Bio-informatics, Biostatistics, Epidemiology and computational Systems Biology of Cancer», Institut Curie, Paris; INSERM U897 Epidemiologie-biostatistique, Bordeaux

Medical Ethics Certificate

June 2014

Bordeaux University Medical School

Bordeaux, France

M.D., Public Health Specialization

2003-2009

Bordeaux University Hospital and Bordeaux University Medical School

Bordeaux, France

M.S. Public Health (Biostatistics and Epidemiology)

2007

Bordeaux School of Public Health (ISPED), Bordeaux University

Bordeaux, France

Medical Scientific Communication Certificate

2006

Bordeaux School of Public Health, Bordeaux University

Bordeaux, France

B.S. Medical Studies

1996-2003

University Descartes. Paris-Quest Medical School

Paris, France

Additional Course

- | | |
|--|--|
| Ethical & Regulatory Aspects of Clinical Research | NIH Clinical center, Bethesda (USA), 2014-15 |
| Diagnostic accuracy (2 days, Pr P. Bossuyt, Pr J. Deek), | Bordeaux (France), 2012 |
| Adaptive and Bayesian methods in clinical research (3 days, Pr J. Whitehead), | Lancaster (UK), 2012 |
| Statistical methods for ordered categorical data (2 days, Pr J. & A. Whitehead), | Bordeaux (France), 2011 |
| Causal inference from observational data (3 days, Pr M. Hernan, Pr J. Sterne), | Bern (Switzerland), 2010 |

PROFESSIONAL EXPERIENCE

Postdoctoral Research Fellow in Research Ethics	2014-Present
<ul style="list-style-type: none">- Research: Dept of bioethics (Head: C Grady), Clinical Center, National Institutes of Health.<ul style="list-style-type: none">o Ethics & research designs (mentor: C Grady, RN, PhD). Placebo in cancer clinical trials. Designs for vaccine trials. Stepped-wedge design. Pragmatic trials.- Hospital activities: Clinical Center, National Institutes of Health.<ul style="list-style-type: none">o Ethics consultations: Research ethics & clinical ethics consultations. Head: M Danis, MD.o Shadowing Institutional Review Boards (IRB) of intramural research<ul style="list-style-type: none">▪ National Institute of Child Health and Human Development (NICHD). Chair: G Grave, MD.▪ National Human Genome Research Institute (NHGRI). Chair: S Hull, PhD.o Clinical rounds: Oncology rounds (National Cancer Institute), Palliative Care.- Teaching experience:<ul style="list-style-type: none">o Vaccines and ethics, Georgetown University Medical Center; MICB-801 course, Interdisciplinary Seminars in Global Infectious Diseases. MS degree candidates in the Biomedical Science Policy & Advocacy Programo Journal club for summer NIH students. Title: Placebo use in cancer randomized clinical trials. Ethics and scientific appraisal. (June-July 2015)o Tutoring a student in the Dept of Bioethics (June 2015 -ongoing)- Social secretary of the NIH Visiting Fellows Committee.	

Assistant Professor in Epidemiology & Clinical trials	2009-2013
Bordeaux University Hospital, INSERM U897,	Bordeaux, France
<ul style="list-style-type: none">- Hospital activities: Clinical Trial Unit (Unité de Soutien Méthodologique à la Recherche clinique et épidémiologique du CHU de Bordeaux, USMR, Head: Pr G. Chêne), Service d'Information Médicale (Head: Pr R. Salamon), Pôle de Santé Publique, Bordeaux University Hospital.- Teaching: Bordeaux School of Public Health (ISPED), Bordeaux University Medical School,- Research: Centre INSERM U897 Epidémiologie-Biostatistique (Head: Pr C. Tzourio),	

Scientific & research responsibilities

- **Methodological consulting** for the design of protocols for academic grants applications (10 per year).
- **Methodological supervision** (design, conduct, analysis, publication) of 20 studies sponsored by Bordeaux University Hospital. Main topics:
 - o Early phase trials of molecularly targeted agents in oncology
 - o Randomized trials: colorectal surgery; non-pharmacological interventions in oncogeriatrics
 - o Prognostic studies: oncogeriatric patients; cardiotoxicity of chemotherapy.
 - o Screening study: oral cancer
 - o Case-control study in liver cancer.
- Chair of monthly Methodological Seminars of Clinical Epidemiology, Clinical Trial Unit of Bordeaux University Hospital.

- Assistant Head, Data Center for cancer clinical trials (CTD Essais cliniques Bordeaux, Head: Pr S. Mathoulin-Pelissier, approved by the French NCI (INCa)), collaboration with Comprehensive Cancer Center Institut Bergonié.
- Scientific Assistant, Centre d'investigation clinique-épidémiologie clinique de Bordeaux (CIC-EC7), in collaboration with Comprehensive Cancer Center Institut Bergonié, and INSERM.
- Contributed to European research project: *Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN): Formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials*. Comprehensive Cancer Centers, France & EORTC, Brussels (Belgium).

Teaching & Tutoring

- Master of Public Health “Biostatistics and Epidemiology”:
 - o Coordinated “Principles of clinical trials” module.
 - o Teached courses: “Early clinical trials design” course in “Principles of clinical trials” module; “clinical trials”course in “Epidemiology of Cancer” module.
 - o Teached tutorial classes in basic epidemiology.
- Bordeaux School of Public Health Summer Course: coordinated the course “Methods and practice of clinical trials”. Teached course: early clinical trials design.
- Certificate “Methods in clinical research” via Internet: Coordinated “prognostic studies” module.
- Tutorial classes for 1st year medical studies: basics in statistics and epidemiology.
- Supervised medical residents in Public Health (2 per semester).

Residency in Public Health

2003-2009

Bordeaux University Medical School,

Bordeaux, France

- 6 semesters in Biostatistics & Clinical Trial Units (Bordeaux University Hospital; Comprehensive cancer centers: Institut Bergonié, Bordeaux; Curie Institute, Paris),
- 2 semesters in Epidemiologic Research Units (pharmacovigilance & pharmacoepidemiology, environmental epidemiology);
- 2 semesters as a physician in rheumatology and diabetology, at Bordeaux University Hospital.

Other professional activities

- Scientific Secretary for the first Conference francophone d’Epidémiologie Clinique, Bordeaux, 2007.
- **Reviewer for scientific journals:** in the field of clinical trials and epidemiology (Contemporary Clinical Trial, Cancer Chemotherapy and Pharmacology, Revue d’Epidémiologie et de Santé Publique).
- **Reviewer for funding organizations:** Methodological expertise for the French Ministry of Health (academic funding of biomedical research), Institut de Recherche en Santé Publique (IRESP-Aviesan).

AWARDS / GRANTS

- **2010 Emile Aubertin Award from Fondation Bordeaux Université for medical thesis:** *Prescriptions of anxiolytic or hypnotic benzodiazepines in general practice patients: Epidemiologic survey in a national sample of general practitioners about management for withdrawal.* Thèse Med Université Bordeaux Segalen; 2009; N°2009BOR23030. Supervisor: Pr R. Salamon.
- **2010 “Research in public health and epidemiology” grant from INCa (French NCI), as co-investigator.** *Optidose: Design and statistical methods for phase I/II clinical trials of molecularly targeted agents in oncology,* PI: X. Paoletti.
- **2009 Ligue Nationale Contre le Cancer grant,** as co-investigator. *Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN),* PI: Pr F. Bonnemain.
- **2006 Fondation pour la Recherche Médicale (FRM) Grant,** for Master of Science (2006-2007).

PUBLICATIONS

Original articles

- **Doussau A**, Grady C. *Deciphering assumptions about Stepped Wedge Designs: The case of Ebola vaccine research.* (*Under review*).
- **Doussau A**, Geoerger B, Jiménez I, Paoletti X. *Innovations for phase I dose-finding designs in pediatric oncology clinical trials.* Contemp Clin Trials (in press).
- Bourdel-Marchasson I, Diallo A, Bellera C, Blanc-Bisson C, Durrieu J, Germain C, Mathoulin-Pélissier S, Soubeyran P, Rainfray M, Fonck M, **Doussau A**. One-year mortality in older patients with cancer: development and external validation of an MNA-based prognostic score. PlosOne (in press).
- **Doussau A**, Thiébaut R, Geoerger B, Schöffski P, Floquet A, Le Deley MC, Mathoulin-Pélissier S, Rizzo E, Fumoleau P, Le Tourneau C, Paoletti X. *A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.* Ann Oncol. 2015;26(2):422-8
- Paoletti X, **Doussau A**, Ezzalfani M, Rizzo E, Thiébaut R. *Dose finding with longitudinal data: simpler models, richer outcomes.* Stat Med. 2015;34(22):2983-98
- Vendrely V, B. Henriques de Figueiredo, E. Rio, J. Benech, S. Belhomme, A. Lisbona, E. Frison, **A. Doussau**, N. Nomikossoff, M. A. Mahé, G. Kantor, J. P. Maire. French Multicenter Clinical Evaluation of Helical TomoTherapy® for Anal Cancer in a Cohort of 64 Consecutive Patients. Radiation Oncology 2015;10:170.
- Pham-Ledard A, Cowpli-Bony A, **Doussau A**, Prochazkova-Carlotti M, Laharanne E, Jouary T, Belaud-Rotureau MA, Vergier B, Merlio JP, Beylot-Barry M. *Diagnostic and Prognostic Value of BCL2 Rearrangement in 53 Patients With Follicular Lymphoma Presenting as Primary Skin Lesions.* Am J Clin Pathol. 2015;143(3):362-73.
- Bouabdallah K, Furst S, Asselineau J, Chevalier P, Tournilhac O, Ceballos P, Vigouroux S, Tabrizi R, **Doussau A**, Bouabdallah R, Mohty M, Le Gouill S, Blaise D, Milpied N. *90Y-ibritumomab tiuxetan, fludarabine, busulfan and anti-thymocyte globulin reduced intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.* Ann Oncol. 2015;26(1):193-8.
- **Doussau A**, Perez P, Puntous M, Calderon J, Jeanne M, Rondeau V, Rozec B, Germain C, Chêne G, Ouattara A, Janvier G. *Fresh Frozen Plasma transfusion did not reduce 30-day mortality in cardiopulmonary-bypass cardiac surgery patients with excessive bleeding. The PLASMACARD multicenter cohort study.* Transfusion. 2014;54(4):1114-24.
- Bourdel-Marchasson I, Blanc-Bisson C, **Doussau A**, Germain C, Blanc JF, Dauba J, Lahmar C, Terrebonne E, Lecaille C, Ceccaldi J, Cany L, Lavau-Denes S, Houede N, Chomy F, Durrieu J,

- Soubeyran P, Senesse P, Chene G, Fonck M. *Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: A two-year randomized controlled trial.* PLoS One. 2014;9(9):e108687.
- Bonnetain F, Bonsing B, Conroy T, **Doussau A**, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpere JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L. *Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).* Eur J Cancer. 2014;50(17):2983-93.
 - Richert L, **Doussau A**, Lelièvre JD, Arnold V, Rieux V, Bouakane A, Lévy Y, Chêne G, Thiébaut R. *Accelerating clinical development of HIV vaccine strategies-methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.* Trials. 2014;15:68.
 - Floquet A, **Doussau A**, Brouste V, Cany L, Dutin JP, Mathoulin-Pélissier S. *Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study.* Cancer Chemother Pharmacol. 2014;73(1):61-8.
 - **Doussau A**, Thiebaut R, Paoletti X. *Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.* Stat Med. 2013;32(30):5430-47.
 - Bellera CA, Pulido M, Gourgou S, Collette L, **Doussau A**, Kramar A, Dabakuyo TS, Ouali M, Auperin A, Filleron T, Fortpied C, Le Tourneau C, Paoletti X, Mauer M, Mathoulin-Pélissier S, Bonnetain F. *Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.* Eur J Cancer. 2013;49(4):769-81.
 - **Doussau A**, Asselain B, Le Deley MC, Geoerger B, Doz F, Vassal G, Paoletti X. *Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline framework.* Contemp Clin Trials. 2012;33(4):657-65.
 - Prey S, Ezzedine K, **Doussau A**, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Hachulla E, de Korwin-Krokowski JD, Kostrzewa E, Quemeneur T, Paul C, Schaeverbeke T, Seneschal J, Solanilla A, Sparsa A, Bouchet S, Lepreux S, Mahon FX, Chene G, Taieb A. *Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.* Br J Dermatol. 2012;167(5):1138-44.
 - Jouary T, Leyral C, Dreno B, **Doussau A**, Sassolas B, Beylot-Barry M, Renaud-Vilmer C, Guillot B, Bernard P, Lok C, Bedane C, Cambazard F, Misery L, Estève E, Dalac S, Machet L, Grange F, Young P, Granel-Brocard F, Truchetet F, Vergier B, Delaunay MM, Grob JJ. *Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study.* Ann Oncol. 2012;23(4):1074-1080.
 - Berger F, **Doussau A**, Gautier C, Gros F, Asselain B, Reyal F. *Impact du statut socioéconomique sur la gravité du diagnostic initial de cancer du sein.* Rev Epidemiol Sante Publique. 2012;60(1):19-29.
 - Durrieu J, **Doussau A**, Rieger A, Terrebonne E, Bouabdallah K, Zwolakowski M-D, Maget B, Dauba J, Mariette C, Trager S, Périé J-L, Robert B, Regueme SC, Bourdel-Marchasson I. *Design of a physical activity program to prevent autonomy decline in onco-geriatric patients (CAPADOGE): A randomized multicenter trial.* J. of Frailty & Aging. 2012;1(3):138-143.
 - Boyer A*, **Doussau A***, Thiébaut R, Venier AG, Tran V, Boulestreau H, Bébérard C, Vargas F, Hilbert G, Gruson D, Rogues AM. *Pseudomonas aeruginosa acquisition on an endemic intensive*

- care unit: the relationship between antibiotic selective pressure and patients' environment.* Crit Care 2011;9(1):R55. *equal contributors
- Dubois O, Salamon R, **Doussau A**, Maurice-Tison S. *Prise en charge psychoéducative pour sevrage de benzodiazépines en cure thermale (et enquête auprès de médecins généralistes).* Annales médico-psychologiques. 2011;169(6):391-4.
 - Paoletti X, Postel-Vinay S, Servois V, **Doussau A**, Ollivier L, Le Tourneau C. *Méthodes pour la recherche de dose de traitements ciblés : nouvelles pistes.* Bulletin du cancer 2010;97(12):1485-95.
 - Paoletti X, **Doussau A**, Geoerger B, Aerts I, Ledele MC, Vassal G, Doz F. *Multi-group Dose-finding Trials in Children: Learning from Adults Trials.* Treatment Strategies – Oncology, 2011.
 - Garrigue I, **Doussau A**, Asselineau J, Bricout H, Couzi L, Rio C, Merville P, Fleury H, Lafon ME, Thiébaut R. *Prediction of cytomegalovirus (CMV) plasma load from evaluation of CMV whole-blood load in samples from renal transplant recipients.* J Clin Microbiol. 2008;46(2):493-8.
 - Traissac L, Chene G, Devars F, Houliat T, Essalki I, Bekhar H, **Doussau A**. *Voice rehabilitation after total laryngectomy using the Newvox voice prosthesis.* Rev Laryngol Otol Rhinol (Bord). 2007; 128(3):163-72.
 - **Doussau A**, Thiessard F, Miremont-Salamé G, Conri C, Haramburu F, et les Centres Régionaux de Pharmacovigilance. *Effets indésirables psychiatriques des fluoroquinolones : analyse des cas de la base de données de pharmacovigilance française,* Rev Med Interne. 2006; 27(6):448-52.
 - Daveluy A, **Doussau A**, Thiessard F, Miremont-Salamé G, Moore N, Haramburu F et le réseau des Centres régionaux de pharmacovigilance. *Inhibiteurs de la recapture de la sérotonine et acné.* Therapie 2006; 61:71-72.

Book chapters

- Paoletti X, **Doussau A**. *Dose Finding Methods in Oncology: From the Maximum Tolerated Dose to the Recommended Phase II Dose.* In: van Montfort K, Oud J, Ghidley W, editors. *Developments in Statistical Evaluation of Clinical Trials.* New York: Springer; 2015. p. 333-58.
- Pereira B, **Doussau A**, Mathoulin-Pélissier S. *Mise en œuvre d'un essai clinique de phase II.* In: John Libbey Eurotext, editor. *Méthodes biostatistiques appliquées à la recherche clinique en cancérologie.* Montrouge 2011. p. 281-300.

Oral presentations (International conferences)

- **Doussau A**, Grady C. *Scientific and Ethical Advantages and Disadvantages of Designs for Vaccine Trials: Stepped-Wedge, Parallel, and Cluster Randomized Designs,* American society for Bioethics and humanities (ASBH), Houston, Texas, USA, 2015.
- **Doussau A**, Fojo T, Colloca L, Grady C. *Ethical tension in cancer randomized controlled trials using placebo: a review of recently published trials.* Society for Clinical Trials (SCT), Arlington, Maryland, USA, 2015.
- **Doussau A**, Thiebaut R, Paoletti X. *Phase I dose finding methods using longitudinal data and proportional odds model in oncology.* Conference of the International Society of Clinical Biostatistics (ISCB), Bergen, Norway 2012.
- Paoletti X, **Doussau A**, Thiébaut R. *Phase I dose finding methods using longitudinal data and proportional odds model in oncology,* International Biometric Society, International Biometric Conf., Kobe, Japan, 2012
- **Doussau A**, Le Deley MC, Paoletti X. *Dose finding methods in pediatric trials: methods comparison in a temporal framework.* Conference of the International Society for Clinical Biostatistics (ISCB), Montpellier, 2010.

Poster presentations (International conferences)

- **Doussau A**, Grady C. *Stepped Wedge Designs for Investigating Therapeutics and Vaccines: Review of past and ongoing trials.* NIH Research Festival, Bethesda, USA, 2015.
- **Doussau A**, Thiebaut R, Geoerger B, Le Deley MC, Schöffski P, Floquet A, Mathoulin-Pélissier S, Rizzo E, Fumoleau P, Paoletti X. *A new approach to integrate the grade of toxicity and later cycles in the analysis and reporting of phase I dose finding trials.* European Cancer Congress (ECCO) Amsterdam, 2013. Society for Clinical Trials (SCT), Arlington, USA, 2015.
- Richert L, **Doussau A**, Lelièvre JD, Arnold V, Lévy Y, Chêne G, Thiébaut R. *Construction of an Optimized Multi-Arm Phase I-II Trial Design to Evaluate the Safety and Immunogenicity of Different HIV Vaccine Strategies.* AIDS vaccine conference, Barcelona, Spain, 2013
- Richert L, **Doussau A**, Lelièvre JD, Arnold V, Lévy Y, Chêne G, Thiébaut R. *Optimization of a randomized multi-arm phase I-II trial design to evaluate the safety and immunogenicity of different HIV vaccine strategies.* 34th annual conference of the International Society for Clinical Biostatistics (ISCB), Munich, Germany, 2013.
- Bonnemain F, **Doussau A**, Mathoulin-Pélissier S, Bonsing BA, Glimelius B, Haustermans K, Conroy T, Van Laethem JL, Labianca R, Macarulla T, Mauer ME, Lutz MP, Tabernero J, De Gramont A, Hammel P, Aust DE, Ducreux M, Taïeb J, Neoptolemos JP, Collette L, DATECAN. *International experts' panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer.* Annual meeting of the American Society of Clinical Oncology (ASCO), Chicago USA, 2012.
- **Doussau A**, Perez P, Puntous M, Calderon J, Jeanne M, Rozec B, Rondeau V, Chêne G, Janvier G for the PLASMACARD Study Group. *Is fresh frozen plasma transfusion associated with 30-day survival following excessive bleeding in cardiopulmonary-bypass cardiac surgery patients?* Transfusion Alternatives in Transfusion Medicine 2008; 10(S1)29. Symposium of Network for Advancement of Transfusion Alternatives (NATA), Lisboa, Portugal, 2008.
- **Doussau A**, Cantagrel-Gruber A, Verdoux H, Baldi I. *Long-term occupational exposure to pesticides and anxiety, depressive or bipolar disorders in a population of French farmworkers.* 13th European Symposium of the Association of European Psychiatrists (AEP), Section Epidemiology and Social Psychiatry, Bordeaux, 2006.

Invited presentations

- *Review of designs of randomized controlled trials using a placebo in cancer patients (Not just a sugar pill).*
 - o Biometric Research Branch, National Cancer Institute (NCI), NIH, Rockville, USA, 2015.
 - o Institut Gustave Roussy, Biostatistics and Epidemiology Department, Villejuif, France, 2015.
 - o Office of Biostatistics Research, National Heart, Lung and Blood Institute (NHLBI), NIH, Bethesda, USA, 2016.
- *Stepped Wedge Design for Investigating Therapeutics and Vaccines: Review of past and ongoing trials.* Faculte de Médecine, Université Paul Sabatier, Toulouse, 2015.
- *Utilisation de modèles mixtes pour données ordinaires répétées de toxicité dans les essais de phase I de recherche de dose,* Séminaires du service de Biostatistique et Épidémiologie de l'Institut Gustave Roussy (Comprehensive Cancer Center), Villejuif/Paris, 2013.
- *A new approach to integrate the grade of toxicity and later cycles in the analysis and reporting of phase I dose finding trials.* Séminaire scientifique annuel du SIRIC « Bordeaux Recherche Intégrée Oncologie, BRIO », labelled by the French NCI (INCa), 2013.

- Méthodologie des essais précoces. Journées scientifiques du Cancéropôle Grand Sud-Ouest, Montpellier, 2012.
- **Doussau A**, Rullier E. *Essai randomisé de phase III comparant la tumorectomie à l'exérèse rectale pour des adénocarcinomes T2-T3 du bas rectum bons répondeurs après radio-chimiothérapie.* Symposium de l'Institut National du Cancer (INCa) : Bilan et suivi du programme hospitalier de Recherche clinique, 22^{ème} International Congress of Anticancer Treatment, Paris, 2011.

Oral presentations (France)

- **Doussau A**. *Evaluation des performances des schémas d'essais de recherche de dose en oncologie par simulations.* 4^{ème} colloque du club « Statistiques et mathématiques appliquées au cancer » du Cancéropôle GSO. Thème : Modélisation et simulation d'essais cliniques. Toulouse, 2015
- Richert L, **Doussau A**, Lelièvre JD, Arnold V, Lévy Y, Chêne G, Thiébaut R. *Optimisation d'un schéma d'essai de phase I-II randomisé pour évaluer la tolérance et l'efficacité de différentes stratégies vaccinales contre le VIH.* 7^e Conférence Francophone d'Epidémiologie Clinique, Paris 2013
- Baschet L, Fricain JC, Meddeb M, Perez P, **Doussau A**. *Reproductibilité inter-observateur de l'autofluorescence tissulaire pour le dépistage des lésions précancéreuses de la cavité buccale, en population alcoololo-tabagique (étude FluoK).* 7^e Conférence Francophone d'Epidémiologie Clinique, Paris 2013
- **Doussau A**, Thiebaut R, Paoletti X. *Analyse de données de toxicité longitudinale dans les essais cliniques de phase I : identification d'une dose cible et détection d'un effet cumulé au cours du temps, à l'aide d'un modèle à odds proportionnels.* Sixième conférence francophone d'épidémiologie clinique (congrès thématique de l'ADLEF-RFUEC) et Journées des Statisticiens des Centres de Lutte contre le Cancer, Lyon 2012.
- **Doussau A**, Thiebaut R, Postel-Vinay S, Gomez-Rocca C, Kaye S, Soria JC, Paoletti X. *Méthodes de modélisation pour l'analyse de données de toxicité répétées dans les essais cliniques – application sur des données d'essais cliniques de phase I en cancérologie.* Journées des Statisticiens des Centres de Lutte contre le Cancer, Lille, 2011.
- **Doussau A**, Le Deley MC, Asselain B, Vassal G, Paoletti X. *Schéma de recherche de dose dans les essais de phase I : comparaison par simulations dans un cadre temporel.* Quatrième conférence francophone d'épidémiologie clinique (ADELF-RFUEC) et Journées des Statisticiens des CLCC, Paris, 2010.
- **Doussau A**, Rullier E, Asselineau J, Chêne G. *Critères de jugement composites dans les essais cliniques. A propos de l'essai GRECCAR 2 : Etude de phase III comparant la tumorectomie à l'exérèse rectale pour des adénocarcinomes T2-T3 du bas rectum bons répondeurs après radio-chimiothérapie.* Journées du Cancéropôle Grand Sud-Ouest, Limoges, 2009.
- **Doussau A**, Perez P, Puntous M, Calderon J, Jeanne M, Rondeau V, Germain C, Chêne G, Janvier G pour les investigateurs de l'étude PLASMACARD. *Transfusion de Plasma Frais Congelé : relation avec la mortalité à 30 jours après saignement grave en chirurgie cardiaque avec circulation extra-corporelle.*
 - Rev Epidemiol Sante Publique 2008, 10(S2)56S. Deuxième conférence francophone d'épidémiologie clinique (ADELF-RFUEC), Nancy 2008.
 - Ann Fr Anesth Reanim. 2008;27S (Hors-Série 1):S135. Congrès de la Société Française d'Anesthésie Réanimation, Paris, 2008.
- **Doussau A**, Gotreau C, Thiessard F, Miremont-Salamé G, Haramburu F, Barcat D, Constans J, Conri C. *Effets indésirables psychiatriques des fluoroquinolones.* Congrès de la Société Française de Médecine Interne, Nantes, 2005.

Poster presentations (France)

Available on request

ADDITIONNAL SKILLS

- **Software:** SAS, R, EndNote.
- Languages: French (native), English (fluent), Spanish (beginner), Russian (beginner).